News | January 18, 2013

Compact Proton Therapy Technology Achieves Milestone of Beam at Gantry Room Isocenter

ProTom Radiance 330

January 18, 2013 — Testing of a compact cancer treatment technology from ProTom International Inc. has demonstrated that the system achieves its design specification: delivering high-energy protons to isocenter at a beam intensity sufficient for standard clinical practice. The ProTom technical team measured stable and reproducible performance on the Radiance 330 proton therapy system at the McLaren Proton Therapy Center (MPTC) in Flint, Mich. This is the first time that ProTom has tested its compact system’s gantry beam optics design.

“Measuring high beam intensities at isocenter indicates well-functioning integration among various subsystems of the Radiance 330 necessary for clinical implementation,” said Vahagn Nazaryan, Ph.D., senior vice president of physics for ProTom. “We delivered beam through the gantry and nozzle in the first of three gantry treatment rooms as part of validation and verification of our technical design. We are pleased that the system performed as designed and quickly achieved a dose rate sufficient for standard clinical practice.”

“We are excited by the results of successful beam transport testing through our first gantry treatment room: these results were independently reproduced by our clinical physics team,” said Sung Park, Ph.D., chief physicist for McLaren Cancer Institute.

Earlier in the summer, ProTom installed a new custom-designed radiofrequency quadrupole (RFQ) proton linear accelerator (linac) injector from AccSys Technology Inc. This upgrade has significantly improved accelerated proton beam intensities. The RFQ upgrade resulted in an increase in injection intensity, yielding in excess of several times the number of protons per cycle accelerated in the synchrotron, with further tuning and optimization ongoing at McLaren.

“Both the ProTom and McLaren teams are to be commended for achieving this very significant result, which continues to validate that the system is performing as it was designed,” said ProTom CEO Stephen L. Spotts. “ProTom is focused on final validation and testing in order to secure all regulatory clearances necessary for clinical operation. It is my firm belief that our Radiance 330 system is not only the most advanced proton beam scanning system available but the most economical solution as well.“

The Radiance 330 proton therapy system has not been cleared by the U.S. Food and Drug Administration (FDA) for commercial distribution in the United States at this time.

For more information:,

Related Content

First Hospitals Achieve Inter-System Connectivity Across Accuray Radiation Therapy Platforms
News | Radiation Therapy | January 19, 2018
Accuray Inc. announced recently that the Heidelberg University Hospital in Heidelberg, Germany, and Oscar Lambret...
RayStation Selected for New Carbon Ion Therapy Center in Japan
News | Treatment Planning | January 18, 2018
January 18, 2018 – RayStation has been chosen as the treatment planning system for a new carbon-ion therapy facility
Raysearch Receives First Order for the Raycare Oncology Information System
News | Oncology Information Management Systems (OIMS) | January 18, 2018
January 18, 2018 – Anderson Regional Cancer Center (ARCC) in Meridian, Mississippi, has placed the first order for...
Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
Overlay Init